Krystal Biotech (NASDAQ:KRYS – Get Free Report) and Roivant Sciences (NASDAQ:ROIV – Get Free Report) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, dividends, risk, institutional ownership, profitability, analyst recommendations and valuation.
Profitability
This table compares Krystal Biotech and Roivant Sciences’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Krystal Biotech | 54.82% | 19.34% | 17.65% |
| Roivant Sciences | -3,534.96% | -22.94% | -21.53% |
Volatility & Risk
Krystal Biotech has a beta of 0.5, indicating that its share price is 50% less volatile than the S&P 500. Comparatively, Roivant Sciences has a beta of 1.1, indicating that its share price is 10% more volatile than the S&P 500.
Earnings & Valuation
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Krystal Biotech | $440.48 million | 22.31 | $204.83 million | $7.98 | 41.61 |
| Roivant Sciences | $8.26 million | 3,024.82 | -$299.77 million | ($0.53) | -65.26 |
Krystal Biotech has higher revenue and earnings than Roivant Sciences. Roivant Sciences is trading at a lower price-to-earnings ratio than Krystal Biotech, indicating that it is currently the more affordable of the two stocks.
Insider and Institutional Ownership
86.3% of Krystal Biotech shares are held by institutional investors. Comparatively, 64.8% of Roivant Sciences shares are held by institutional investors. 13.1% of Krystal Biotech shares are held by insiders. Comparatively, 8.8% of Roivant Sciences shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Analyst Ratings
This is a summary of recent recommendations and price targets for Krystal Biotech and Roivant Sciences, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Krystal Biotech | 0 | 2 | 10 | 2 | 3.00 |
| Roivant Sciences | 1 | 2 | 10 | 1 | 2.79 |
Krystal Biotech presently has a consensus target price of $377.20, suggesting a potential upside of 13.59%. Roivant Sciences has a consensus target price of $45.64, suggesting a potential upside of 31.94%. Given Roivant Sciences’ higher possible upside, analysts plainly believe Roivant Sciences is more favorable than Krystal Biotech.
Summary
Krystal Biotech beats Roivant Sciences on 11 of the 14 factors compared between the two stocks.
About Krystal Biotech
Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.
About Roivant Sciences
Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It develops VTAMA, a novel topical for the treatment of psoriasis and atopic dermatitis; batoclimab and IMVT-1402, the fully human monoclonal antibodies targeting the neonatal Fc receptor across various IgG-mediated autoimmune indications; and RVT-3101, an anti-TL1A antibody for ulcerative colitis and Crohn's disease. The company was founded in 2014 and is based in London, the United Kingdom.
Receive News & Ratings for Krystal Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Krystal Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
